

Lupin gets MHRA Approval for Lisinopril in UK

BSE : 500257

NSE: Lupin

REUTERS: LUPN.BO

BLOOMBERG: LPC IN

Mumbai, 2 July 2007: Lupin Ltd. announced that it has received approval for generic Lisinopril 2.5mg, 5mg, 10mg and 20mg tablets from the UK MHRA. Lisinopril is an ACE inhibiting drug used for treating hypertension and congestive heart failure.

Lupin's Lisinopril tablets would be the generic equivalent of Merck's Prinivil tablets. Sales of Prinivil tablets in UK are close to USD 46 million as per IMS. Commercial shipments are planned shortly.

"The MHRA approval of Lisinopril tablets is our first oral generic product approval in UK. We are market leaders in this molecule in the US and we hope to emulate our success in Europe as well. This approval is the first of a series of approvals that we expect in UK and Europe in the next few months," said Dr. Kamal Sharma, Managing Director, Lupin Ltd.

About Lupin

Headquartered in Mumbai, Lupin Ltd. is a leading pharmaceutical company with strong research focus. It has a programme for developing New Chemical Entities. The Company has state-of-the-art R&D center in Pune. The Company is a leading global player in Anti-TB, Cephalosporins (anti-infectives) and Cardiovascular drugs (prils and statins) and has a notable presence in the areas of diabetology, NSAIDS and Asthma.

For the financial year ended March 2007, Lupin's Revenues and Profit after Tax were Rs.20,289 million (US\$ 475 million) and Rs. 3,021 million (US\$ 70 million) respectively.

For further information contact:

Raju Kane

The Source

Tel. +91 22 24901327/28

Telefax: +91 22 24901325

Mobile: +91 98200 45656

E-mail: rajukane@sourcepr.com